Beneficiary Advisory Panel Handout
Uniform Formulary Decisions
27 Sept 2012

PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review.

Table 1: Testosterone Replacement Therapy

Formulary Agents: Fortesta gel pump – step preferred

Formulary with documented trial or contraindication:

Androderm patch
Striant buccal tabs
Testim gel packets

Non-formulary with a documented trial or contraindication to Fortesta gel:

Axiron lotion pump
Androgel gel packet and pumps

Recommended implementation period: 90 days

Figure 1: 30-Day Equivalents in All Points of Service



Table 2: Heparin and Related Products Low-Molecular Weight Heparins

Formulary: enoxaparin (Lovenox, generics)
dalteparin (Fragmin, generic)
fondaparinux (Astrix)

Non-formulary: None

Figure 2: 30-Day Equivalents in All Points of Service



Table 3: Targeted Immunomodulatory Biologics

Formulary:

Adalimumab (Humira)
Alefacept (Amevive)

Non-formulary:

Etanercept (Enbrel)
Anakinra (Kineret)
Golimumab (Simponi)
Certolizumab (Cimzia)
Abatacept (Orencia) – New Drug Reviewed

Implementation Plan: 60 Days

Figure 3: TIB Utilization in 30-Day Equivalents in All Points of Service



Table 4: Ophthalmic Prostaglandins

Formulary:

Latanoprost (Xalatan)
Bimatoprost (Lumigan)

Non-formulary:

Travoprost (Travatan Z)
Tafluprost (Merck) – New Drug Reviewed

Implementation Plan: 60 Days

Figure 4: Ophthalmic Prostaglandins Utilization in 30-Day Equivalents in All Points of Service



Table 5: Oral Non-steroidal Anti-inflammatory Drugs

Formulary:

ibuprofen 400 mg, 600 mg & 800 mg (generic)
indomethacin 25 mg & 50 mg (generic)
meloxicam 7.5 mg & 15 mg (generic)
naproxen 250 mg 500 mg & 125 mg/5 mL susp (generic)
celecoxib (Celebrex)
diclofenac/misoprostol (Arthrotec)
diclofenac potassium tablets (Cataflam generic)
diclofenac sodium tablets (Voltaren generic)
diflunisal
etodolac
fenoprofen
flurbiprofen
ketoprofen
ketorolac
meclofenamate
nabumetone
naproxen sodium 275 mg & 550 mg (Anaprox, generic)
oxaprozin
piroxicam
sulindac
tolmetin
naproxen/esomeprazole (Vimovo)

Non-formulary:

diclofenac potassium liquid filled capsules (Zipsor) 25 mg
diclofenac potassium powder packets 50 mg (Cambia)
naproxen sodium ER (Naprelan CR, generic) 375 mg, 500 mg, & 750 mg ER tabs, dosing card
mefenamic acid (Ponstel, generic) 250 mg
ibuprofen/famotidine (Duexis) – New Drug Reviewed
ketorolac nasal spray (Sprix) – New Drug Reviewed

Implementation Plan: 60 Days

Figure 5: Oral Non-steroidal Anti-inflammatory Drugs Utilization in 30-Day Equivalents in All Points of Service



Table 6: DPP-4 Inhibitors

Formulary: Step-preferred

Sitagliptin (Januvia)
Sitagliptin/Metformin (Janumet)
Sitagliptin/Metformin XR (Janumet XR) – New Drug Reviewed
Linagliptin (Tradjenta)
Sitagliptin/Simvastatin (Juvisync)
Linagliptin/Metformin (Jentadueto) – New Drug Reviewed

Non-formulary:

Saxagliptin (Onglyza)
Saxagliptin/Metformin (Kombiglyze XR)

Implementation Plan: 60 Days

Figure 6: DPP-4 Inhibitors Utilization in 30-Day Equivalents in All Points of Service



Table 7: Table of Implementation Status of UF Recommendations/Decisions Summary Table

Meeting	Drug Class	Non-formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Step Therapy
				MTF	Retail	Mail Order		
Aug 2012	**Targeted Immuno-modulatory Biologics**	Abatacept (Orencia)	542	59	351	132	60 days	NA
	Ophthalmic Prostaglandins	Tafluprost Ophthalmic Solution (Zioptan)	234	2	182	50	60 days	NA
	NSAIDS	Ketorolac (Sprix)	2,885	424	2,427	34	60 days	NA
		Famotidine/ibuprofen (Duexis)	1,137	1	1,060	76		
	Testosterone Replacement Therapy	Axiron lotion pump	2,732	19	2,376	337	90 days	Must try Fortesta products first
		Androgel gel packet/pumps	22,943	5,069	13,739	4,136		